Pneumonitis From Anti–PD-1/ PD-L1 Therapy
October 15th 2017While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.